Latanoprost

Class: Prostaglandin Analogs
VA Class: OP109
Molecular Formula: C₂₆H₄₀O₅
CAS Number: 130209-82-4
Brands: Xalatan, Xelpros

Medically reviewed by Drugs.com on Oct 19, 2020. Written by ASHP.

Introduction

Ocular hypotensive agent; a synthetic analog of prostaglandin F_2α (PGF_2α).

Uses for Latanoprost

Ocular Hypertension and Glaucoma

Latanoprost 0.005%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Appears to be more effective than unoprostone (not available in US), as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

May be more effective or at least as effective as twice-daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be more effective than thrice-daily administration of dorzolamide 2%.

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.

Fixed-combination netarsudil 0.02% and latanoprost 0.005%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. When administered once daily, mean IOP reduction was approximately 1–3 mm Hg greater than that achieved with once-daily administration of either drug alone.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors....